skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
español
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page


<< Back

Funding

Innovation for HIV Vaccine Discovery (R01)

Description
Grant Amount: Estimated total of $3.05M in total costs in FY 2014 in response to this FOA.

The purpose of this Funding Opportunity Announcement (FOA) is to foster original, high risk, and unconventional research that, if successful, may have a substantial impact on approaches to HIV/AIDS vaccine discovery and development. Applicants must clearly state how their proposed new idea, approach and rationale:

(1) offer a potential solution for preventing acquisition of infection,

(2) could be stringently tested (e.g., in a vaccine animal challenge model) and potentially implemented,

(3) differ from current or previously failed approaches, and

(4) will contribute, inform, or provide more than incremental knowledge to the field regardless of the outcome of the proposed work.

Recent advances in biomedical technologies, such as molecular and structural imaging, deep sequencing, and new ways of probing the antibody repertoire, have generated insight into the virology and immunology of HIV. Clearly, a more intense effort focused on the application of these evolving research tools poses an exciting potential for vaccine discovery. Projects proposed will be expected to explore and test novel hypotheses that, if successful, would significantly impact the design of immunogens or immunization strategies leading to an effective HIV vaccine.

Preventing acquisition of HIV infection encompasses events associated with infecting initially susceptible cells, local propagation, and initial dissemination of virus from the first infected cells. For the purpose of this FOA, HIV acquisition is defined to encompass the initial infection of susceptible target cells at sites of entry, as well as the early dissemination of HIV from a local infection to nearby or distant tissues before latency of infection is established. Under this definition, initial infection involves the process of a target cell acquiring the virus from an infected source. Then the target cell replicates virus and subsequently transmits infectious virus to new target cells. An infectious source could be secretions (fluid or blood) carrying free virus or infected cells. This process can be halted by preventing the initial infection of target cells, or by preventing the active or passive spread of virus from the initial infection foci to new target cells. Therefore, blocking the initial entry of the virus into a host and/or preventing/inhibiting/reducing its subsequent replication such that initial spread of infection is aborted may result in protection of the host from HIV acquisition and infection. These processes could include innate and adaptive immunological processes that may promote, inhibit and/or delay infection of target cells and spread of HIV.




Funding Organization
National Institute of Allergy and Infectious Diseases
Division of AIDS
Fund Category
HIV/AIDS
Support Types
Research
Locations
International
National
Eligible Organizations
City Agencies
Colleges/Universities
Commercial Organizations
Community Based Organizations
County Agencies
Educational Organizations/Institutions
Federal Government Agencies
International Agencies
IRS 501 (c)(3) Organizations
Nonprofit Organizations
Religious Organizations
Schools
State Agencies
Tribal Organizations
Number of Awards Given
5 - 10 awards
Award Amount Notes
NIAID intends to commit an estimated total of $3.05M in total costs in FY 2014 to fund 5-10 applications submitted in response to this FOA.

Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Letter of Intent Date
6/24/2013
Application Due Date
7/24/2013
Project Start Date
6/1/2014
Application Contact
Grants.gov Customer Support
,
Phone: (800) 518-4726
Technical Contact
Jon Warren
NIAID
Phone: (301) 402-0633
Fund Duration
Up to 4 years.
Subjects
HIV/AIDS Prevention
Vaccine Development Research
Audiences
Researchers
Application Process
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Web Site
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-007.html
Fund Number
RFA-AI-13-007

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.

cdcnpin.org Fund Record #4625

<< Back

CDCNPIN.org

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources

hivtest.cdc.gov
m.hivtest.cdc.gov
findtbresources.org
STD Awareness Microsite
findstdtest.org
AIDS Gov Logo and Link CDC Logo and Link